REVERSE-AKI Randomized Controlled Pilot Trial

H

Helsinki University Central Hospital (HUCH)

Status and phase

Completed
Phase 2

Conditions

Acute Kidney Injury
Critical Illness

Treatments

Other: Restrictive fluid management

Study type

Interventional

Funder types

Other

Identifiers

NCT03251131
HUS/1782/2017

Details and patient eligibility

About

Observational studies among patients with acute kidney injury (AKI) have shown an association with fluid accumulation and increased mortality. Trials among other subgroups of critically ill patients have demonstrated that restricting fluid input after the initial resuscitation appears safe. The objective if this study is to determine whether a fluid restrictive treatment regimen will lead to a lower cumulative fluid balance at 72 hours from randomization in critically ill patients with AKI and whether this approach is safe and feasible.

Full description

Acute kidney injury (AKI) is common in the critically ill and associates with adverse outcomes. Patients with AKI are frequently have low urine output and are at high risk of developing fluid overload. Fluid overload has been associated with an increased risk for mortality in such patients. Previous trials in critically ill patients found that a 'restrictive fluid therapy' after resuscitation was safe. Implementing a restrictive fluid therapy approach in patients with AKI may also be of benefit. To date, however, no randomized trial has been performed to evaluate the safety and feasibility of implementing a 'restrictive fluid therapy' approach compared to standard fluid therapy in patients with AKI. In this pilot randomized controlled trial we will evaluate the implementation of a fluid restrictive approach, compared to standard therapy, in adult critically ill patients with acute kidney injury.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18-years or older and admitted to critical care with an arterial line in place
  • The patient has been in critical care for at least 12 hours but no more than 72 hours

The patient has AKI but is not receiving acute RRT:

For the purpose of the study AKI is defined the by the following criteria:

  • Increase in serum creatinine over 1.5-times above baseline without a decline of 27umol/l or more from the last preceding measurement (at least 12 hours apart) AND/OR
  • Overall urine output less than 0.5ml/kg/h (or 6ml/kg) for the previous 12h (with urine catheter in place for the period)
  • The patient is judged by the treating clinician not to be intravascularly hypovolemic
  • The patient is likely to remain in critical care for 48 hours after randomization

Exclusion criteria

  • Active bleeding necessitating transfusion
  • Maintenance fluid therapy is necessary due to diabetic ketoacidosis, non-ketotic coma, severe burns or other clinical reason determined by the medical staff
  • Need for RRT due to intoxication of a dialyzable toxin
  • Commencement of RRT is expected in the next 6 hours
  • On chronic renal replacement therapy (maintenance dialysis or renal transplant)
  • Presence or a strong clinical suspicion of parenchymal AKI (for example glomerulonephritis, vasculitis, acute interstitial nephritis), or post-renal obstruction
  • Severe hyponatremia (Na <125mmol/L) or hypernatremia (Na >155mmol/L)
  • Need for extracorporeal membrane oxygenation or molecular absorbent recirculating system (MARS-therapy)
  • Pregnant or lactating
  • Patients who are not to receive full active treatment
  • No baseline creatinine available
  • Lack of consent
  • The patient has been enrolled in another trial where co-enrollment is not feasible

Trial design

100 participants in 2 patient groups

Restrictive fluid management
Experimental group
Description:
Restrictive fluid management Targeting a negative or maximum 300ml positive daily fluid balance.
Treatment:
Other: Restrictive fluid management
Standard therapy
No Intervention group
Description:
Randomized allocation of standard care at the clinician's discretion in accordance with current best practice.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems